Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin.
Am J Med
; 94(4): 401-6, 1993 Apr.
Article
em En
| MEDLINE
| ID: mdl-8475933
ABSTRACT
PURPOSE:
This study investigated the hypothesis that a genetic predisposition to hypertension is involved in the etiology of the elevation in blood pressure induced by human recombinant erythropoietin (rHuEPO). PATIENTS ANDMETHODS:
Blood pressure changes after 10 weeks of treatment with rHuEPO were compared between 26 patients with a positive family history of hypertension and 27 with a negative family history.RESULTS:
Mean blood pressure was significantly increased in patients with a positive family history of hypertension (+8.8 mm Hg, p < 0.001). In contrast, the change was not significant in those whose family history was negative (+1.8 mm Hg, not significant). The mean blood pressure of 14 of 26 patients with a positive family history of hypertension increased by more than 10%, whereas such an increase occurred in only 2 of 27 patients with a negative family history (p < 0.001). The two groups were similar in terms of the total dose of rHuEPO given, the degree to which their anemia improved, and their basal blood pressures.CONCLUSION:
It appears that hemodialysis patients with a positive family history of hypertension are susceptible to developing hypertension during treatment with rHuEPO.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Eritropoetina
/
Diálise Renal
/
Hipertensão
/
Falência Renal Crônica
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1993
Tipo de documento:
Article